Boston Scientific Co. (NYSE:BSX) SVP Wendy Carruthers sold 29,412 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $39.63, for a total transaction of $1,165,597.56. Following the sale, the senior vice president now owns 200,751 shares of the company’s stock, valued at $7,955,762.13. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Boston Scientific stock opened at $40.05 on Friday. The firm has a market capitalization of $55.80 billion, a P/E ratio of 27.24, a PEG ratio of 2.30 and a beta of 0.88. The company has a quick ratio of 0.54, a current ratio of 0.76 and a debt-to-equity ratio of 0.55. Boston Scientific Co. has a fifty-two week low of $26.27 and a fifty-two week high of $41.00.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.02. The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.57 billion. Boston Scientific had a net margin of 17.01% and a return on equity of 25.92%. Boston Scientific’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.34 EPS. On average, sell-side analysts forecast that Boston Scientific Co. will post 1.56 EPS for the current year.

Several research firms have recently commented on BSX. Argus upped their price objective on Boston Scientific from $43.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 13th. Canaccord Genuity restated a “buy” rating and issued a $45.00 price objective on shares of Boston Scientific in a research note on Monday, February 11th. Guggenheim restated a “buy” rating and issued a $48.00 price objective on shares of Boston Scientific in a research note on Friday, February 8th. SunTrust Banks restated a “buy” rating and issued a $47.00 price objective on shares of Boston Scientific in a research note on Friday, February 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective on shares of Boston Scientific in a research note on Wednesday, February 6th. Three equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and two have given a strong buy rating to the company’s stock. Boston Scientific currently has a consensus rating of “Buy” and an average target price of $40.54.

Institutional investors have recently modified their holdings of the stock. We Are One Seven LLC bought a new position in Boston Scientific in the 4th quarter worth $27,000. Athena Capital Advisors LLC bought a new position in Boston Scientific in the 4th quarter worth $28,000. Ipswich Investment Management Co. Inc. bought a new position in Boston Scientific in the 4th quarter worth $28,000. CWM LLC boosted its holdings in Boston Scientific by 54.3% in the 4th quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 359 shares during the period. Finally, West Oak Capital LLC boosted its holdings in Boston Scientific by 40.0% in the 4th quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 300 shares during the period. 91.28% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2019/03/15/insider-selling-boston-scientific-co-bsx-svp-sells-1165597-56-in-stock.html.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: Why is cost of goods sold important?

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.